Results 51 to 60 of about 37,178 (276)

CYP2C9 rs1057910 Genotype and Its Association with Paraclinical Characteristics in Gout Patients in the Northeast Region of Vietnam

Indonesian Biomedical Journal
BACKGROUND: Celecoxib and lesinurad are medications used in the management of gout, and their metabolism is significantly influenced by genetic variations in the CYP2C9 enzyme. CYP2C9*3 (rs1057910) is associated with reduced CYP2C9 activity.
Lan Thi Vu, Yen Thi Thu Hoang, Yen Thi Nguyen, Vien Van Nguyen, Hien Thu Nguyen, Thanh Ha Do, Tuan Phan Hoang   +6 more
doaj   +1 more source

The Effect of Polymorphisms in the CYP2D6 and CYP2C9 Genes on the Clinical Efficacy of Tramadol and Ketorolac When Using the Accelerated Recovery Protocol in Patients With Uncomplicated Acute Calculous Cholecystitis Who Underwent Cholecystectomy

Неотложная медицинская помощь, 2020
Relevance. One of the key components of the accelerated recovery protocols (ARP), in addition to minimizing the surgical approach, is an adequate postoperative analgesia.
A. A. Muradyan, D. A. Blagovestnov, D. A. Sychev, P. A. Yartsev, M. L. Rogal, L. N. Kerimova, V. T. Koroshvili, I. A. Yepifanova   +7 more
doaj   +1 more source

Identification and in vitro functional assessment of 10 CYP2C9 variants found in Chinese Han subjects

Frontiers in Endocrinology, 2023
Cytochrome P450 2C9 (CYP2C9) participates in about 15% of clinical drug metabolism, and its polymorphism is associated with individual drug metabolism differences, which may lead to the adverse drug reactions (ADRs).
Qing Zhang, Qing Zhang, Qing Zhang, Yuying Qi, Yuying Qi, Shuanghu Wang, Fangling Zhao, Fangling Zhao, Lili Zou, Lili Zou, Lili Zou, Quan Zhou, Peiwu Geng, Yun Hong, Yun Hong, Hang Yang, Hang Yang, Qingfeng Luo, Qingfeng Luo, Jianping Cai, Hualan Wu, Hualan Wu, Dongxu Wang, Dongxu Wang, Hao Chen, Hao Chen, Jiefu Yang, Jiefu Yang, Jiefu Yang, Dapeng Dai   +29 more
doaj   +1 more source

Automating AI Discovery for Biomedicine Through Knowledge Graphs and Large Language Models Agents

Advanced Intelligent Discovery, EarlyView.
This work proposes a novel framework that automates biomedical discovery by integrating knowledge graphs with multiagent large language models. A biologically aligned graph exploration strategy identifies hidden pathways between biomedical entities, and specialized agents use this pathway to iteratively design AI predictors and wet‐lab validation ...
Naafey Aamer, Muhammad Nabeel Asim, Shan Munir, Andreas Dengel   +3 more
wiley   +1 more source

Pharmacogenetics: Influence of CYP2C9*2 and *3 alleles polymorphisms on Iraqi type 2 diabetic patients

Medical Journal of Babylon
Background: Sulfonylureas (SUs) are the most prescribed anti-diabetic drugs. The enzyme responsible for metabolizing of SUs is hepatic cytochrome P4502C9 (CYP2C9).
Ghada S. Rasool, Asmaa A. Hussien, Suhad R. Al-Tayie, Salwa J. Al-Awadi, Hussein OM Al-Dahmoshi   +4 more
doaj   +1 more source

CYP2C9 polymorphism in patients with epilepsy: genotypic frequency analyzes andphenytoin adverse reactions correlation

Arquivos de Neuro-Psiquiatria, 2011
OBJECTIVE: CYP2C9 is a major enzyme in human drug metabolism and the polymorphism observed in the corresponding gene may affect therapeutic outcome during treatment. The distribution of variant CYP2C9 alleles and prevalence of phenytoin adverse reactions
Carlos Alexandre Twardowschy, Lineu César Werneck, Rosana Herminia Scola, Luciano De Paola, Carlos Eduardo Silvado   +4 more
doaj   +1 more source

Studies on Regioselective Binding Mode of Steroid Molecules in Homology Modeled Cytochrome P450-2C11 [PDF]

, 2009
In this study, we investigated the regioselective binding mode of steroid molecules and structure requirements for steroid molecules for 16[alpha]-hydroxylation by Cytochrome P450-2C11.
Eiichi Akaho, Hamed I. Ali, Hukihisa Fujita, Morio Yamada   +3 more
core   +1 more source

Warfarin dose and INR related to genotypes of CYP2C9 and VKORC1 in patients with myocardial infarction [PDF]

, 2008
Background Warfarin treatment has a narrow therapeutic range, requiring meticulous monitoring and dosage titration. Individual dosage requirement has recently partly been explained by genetic variation of the warfarin metabolizing enzyme ...
Haug, Kari B F, Sharikabad, Mohammad N, Kringen, Marianne K, Narum, Sigrid, Sjaatil, Stine T, Johansen, Per W, Kierulf, Peter, Seljeflot, Ingebjørg, Arnesen, Harald, Brørs, Odd   +9 more
core   +2 more sources

CYP2C9 Variations and Their Pharmacogenetic Implications Among Diverse South Asian Populations

Pharmacogenomics and Personalized Medicine, 2021
Sheikh Nizamuddin,1,2 Shivendra Dubey,1 Sakshi Singh,1 Saurav Sharma1 ,† Pratheusa Machha,1,3 Kumarasamy Thangaraj1,3,4 1CSIR-Centre for Cellular and Molecular Biology, Hyderabad 500007, India; 2German Cancer Consortium (DKTK) c/o Zentrale ...
Nizamuddin S, Dubey S, Singh S, Sharma S, Machha P, Thangaraj K   +5 more
doaj  

Toward a clinical practice guide in pharmacogenomics testing for functional polymorphisms of drug-metabolizing enzymes. Gene/drug pairs and barriers perceived in Spain [PDF]

, 2012
The development of clinica lpractice recommendations or guidelines for the clinical use of biomarkers is an issue of great importance withr regard to adverse drug reactions.The poten-tial of pharmacogenomicbiomarkers has been extensively investigated in
Abad Santos, Francisco, Aldea, Ana, Alonso-Navarro, Hortensia, Bernal, María Luisa, Borobia, Alberto M., Borràs, Emma, Carballo, Miguel, Carvajal, Alfonso, García-Agúndez, José Augusto, García-Martín, Elena, García-Muñiz, José D., Gervasini, Guillermo, Jiménez-Jiménez, Félix Javier, Lucena, María Isabel, Martínez, Carmen, Sacristán, José A., Salado, Inés, Sinués, Blanca, Vicente, Jorge   +18 more
core   +4 more sources